Skip to content
naulon

Not checkedNot checked for notices yet.

THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE

A. B. Khadzegova

Российский кардиологический журнал · 2014

doi:10.15829/1560-4071-2014-9-72-76 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The prevalence of congestive heart failure (CHF) is growing further with age, and 65% of the sufferers are in the age group from 65 to 80 y.o. Despite success in CHF treatment, mean year mortality is about 6%, and mortality of those with clinically salient CHF reaches 12%. To increase duration of life it is important to prescribe efficient drug therapy, that must include beta-adrenoblockers (BAB), especially in CHF with low ejection fraction (EF) of the left ventricle (LV). Taken into account the results of SENIORS and NEMESIDA, in the year 2013 Nebivolol was included to the National Guidelines on diagnostics and treatment of CHF (IVth review). Benefits on Nebivolol are super-selectivity, vasodilation due to NO release, ability to decrease central aortal pressure, good tolerability and low risk of side effects, especially in patients with concomitant diseases. Nebivolol is effective in coronary heart disease (CHD) and arterial hypertension (AH).

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.